Dianthus Therapeutics, Inc. DNTH
88.55
(2.16)
(2.38%)
as of 25 Sep
- Market cap
- $5.1B
- P/E
- 0.0×
Follow DNTH
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (26.07%) | (22.70%) | (38.38%) | (28.57%) |
+8 more TTM periods Free account |
|
| (24.98%) | (21.77%) | (35.88%) | (27.12%) | ||
ROIC |
(47.74%) | (132.76%) | (124.80%) | (60.96%) | |
Return on Tangible Assets |
(22.26%) | (16.05%) | (42.83%) | (32.38%) | |
Average Days of Receivables |
20.32 | 336.04 | 9.32 | 592.92 | |
Free Cash Flow per Share |
(2.78) | (2.72) | (3.35) | (2.90) | |
Free Cash Flow |
(155.71) | (130.48) | (129.27) | (109.63) | |
Capital Expenditures |
(0.33) | (0.20) | (0.21) | (0.11) | |
Piotroski F-Score |
3.00 | 3.00 | 1.00 | 1.00 | |
| Other line items | |||||
Cash ROIC |
(7.55%) | (5.63%) | (14.38%) | (11.54%) | |
Accounts Receivable Turnover |
26.26 | 1.20 | 4.74 | 0.80 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
9,222.58% | 11,464.30% | 7,153.14% | 3,643.79% | |
Selling, General and Administrative Expense of Revenue |
2,318.80% | 2,953.74% | 1,686.20% | 1,014.62% | |
Share Based Compensation of Revenue |
1,800.00% | 2,101.80% | 1,119.50% | 673.59% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.81 | 0.75 | 0.80 | 0.87 | |
Depreciation/Fixed assets |
(23.11) | (18.65) | (19.37) | (41.28) | |
Capex/Depreciation |
0.03 | 0.04 | 0.04 | 0.01 | |
Revenue per Share |
0.03 | 0.03 | 0.05 | 0.08 | |
Operating CF per Share |
(2.77) | (2.71) | (3.34) | (2.90) | |
Capex per Share |
(0.01) | 0.00 | (0.01) | 0.00 | |
Capex to Sales |
0.18 | 0.15 | 0.10 | 0.03 | |
Net Profit Margin |
(10,096.95%) | (12,998.50%) | (7,973.33%) | (4,104.78%) |
Columns are period end dates